Research article

Pick analysis

History arrow_forward
a sunset view of a mountain range with clouds in the sky
Research brief

Nov 20, 2026 Morning

03:20 PM UTC
Johnson & Johnson JNJ medium
Conf. Medium
Pick Pr. $271.11
Stop Level $263.50
Curr. Pr. $270.20
Change -0.34%
Rem. Days 7

Summary

  • Authoritative Selection: Johnson & Johnson (JNJ) is selected as the sole current S&P 500 pick (verified constituent as of 2026-11-20 10:23:07 EST en.wikipedia.S&P 500 constituent snapshotMembership fetched at 2026-11-20T15:23:07.555050+00:00Visit original website ↗finance.yahooYahoo Finance screener: sp500Universe=sp500Visit original website ↗) for the 7-calendar-day holding horizon (2026-11-20 10:20:01 EST to 2026-11-27 10:20:01 EST, approximately 4.0 regular-session equivalents due to the Thanksgiving Day closure on November 26 and the 1:00 PM EST early close on November 27 nyseHolidays & Trading HoursAll NYSE markets observe U.S. holidays as listed below for 2026, Thanksgiving Day Thursday, November. Each market will close early at 1:00 p.m. (1:15 p.m. for ...Visit original website ↗nyseHolidays & Trading HoursICE NYSE LOGIN Listings Trading Market Data Insights About Trading at NYSE / Holidays & Trading Hours Holidays & Trading Hours All NYSE markets observe U.S. holidays as listed below for 2026, 2027, and 2028. Trading Days Trading Hours Holiday 2026 2027 2028 New Year’s Day Thursday, January 1 Friday, January 1 —* Martin Luther King, Jr. Day Monday, January 19 Monday, January 18 Monday, January 17 Washington's…Visit original website ↗).
  • Fresh Publication Quote Check: The latest market quote for JNJ is $271.075 observed at 2026-11-20 11:21:00 EST (retrieved 11:21:02 EST, +1.47% vs. prior close $267.140 finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), drifting just +0.05% above the decider's authored research entry of $270.935 (2026-11-20 11:10:00 EST finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗) and leaving structural support at $263.50 completely unbroken.
  • Decider Forecast & Ranking Edge: Under the decider's uncalibrated analyst estimates referenced to $270.935, JNJ passes the pre-uncertainty absolute-return gate with +1.1609% expected net return (+0.4609% base excess vs. the decider's +0.70% 7-day SPY benchmark estimate), ranking #1 across all 10 reviewed S&P 500 finalists on uncertainty-adjusted excess return (-1.6391% after a 2.10 pp uncertainty deduction), Expected R (+0.4230), profit-to-stop probability headroom (10.29 pp), and coherent adverse-market stress excess return (+0.3103% vs. -1.18% stressed SPY).
  • Catalyst & Income Cushion: JNJ combines four fresh November 17–20 clinical and commercial milestones—Phase 4 STAR TREMFYA data prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗, CAPLYTA bipolar mania FDA sNDA jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗, first commercial OTTAVA robotic surgical system installation quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗, and RYBREVANT FASPRO FDA accelerated approval patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗—with a confirmed $1.34/share (+0.495%) Q4 ex-dividend on Tuesday, November 24, 2026 investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗ and zero pending company-specific binary events inside the November 20–27 window.
  • Confidence Rationale (Medium, descriptive only): Low-beta (0.20) defensive leadership finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗, deep liquidity ($2.07B 20-day average daily dollar volume finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), and positive stressed excess return support a Medium confidence label, tempered by uncalibrated exit probabilities, elevated Thanksgiving-week macro dispersion, the mechanical November 24 ex-dividend price drop narrowing the stop buffer, and ongoing talc/FDA marketing headline overhang.

Why Now

Recent Developments (November 16–20, 2026): Johnson & Johnson enters the Thanksgiving-shortened week with a dense cluster of objective pipeline and MedTech execution milestones:

  • November 20, 2026: Late-breaking Phase 4 STAR study data showed TREMFYA (guselkumab) is the only advanced therapy demonstrating MRI-confirmed improvements in spinal pain and stiffness in psoriatic arthritis prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗.
  • November 19, 2026: JNJ submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for CAPLYTA in bipolar mania (its fifth potential indication) jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗ and announced the first commercial installation of its OTTAVA robotic surgical system at Memorial Hermann quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗xtenet researchJNJ Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System.Visit original website ↗.
  • November 17–18, 2026: The FDA granted accelerated approval for RYBREVANT FASPRO patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗, following Monday November 16's sweeping $5.5B talc settlement framework ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗ and a $750M Blackstone Life Sciences Phase 3 collaboration xBlackstoneWe're pleased to expand our relationship with Johnson & Johnson through a $750 million agreement for Blackstone Life Sciences to support the Phase 3 ...Visit original website ↗.
  • Confirmed Near-Term Income: JNJ goes ex-dividend on Tuesday, November 24, 2026 for its Q4 quarterly dividend of $1.34/share (+0.495% at $270.935, payable December 8) investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗marketchamelJohnson & Johnson sets $1.34 quarterly dividend with ...Johnson & Johnson's board declared a $1.34 per share cash dividend for the fourth quarter of 2026. The company set November 24, 2026 as the ...Visit original website ↗.

Why Actionable Now vs. Rejected Finalists: None of the November 17–20 clinical or MedTech milestones creates an immediate 7-day EPS step-change; rather, they reinforce defensive institutional rotation into Healthcare while SPY trades -1.21% intraday ($707.190 at 11:10:00 EST) below its $711.486 session VWAP and $730.199 200-day moving average amid AI/semiconductor unwinding finance.yahoYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗. Over the last 20 completed sessions through November 19, JNJ gained +1.26% versus -5.80% for SPY (+7.06 pp relative outperformance) and -1.02% for XLV (+2.28 pp sector alpha) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. After pulling back -2.15% on November 18 and -2.04% on November 19 to test $264.680, JNJ rebounded +1.42% to $270.935 at 11:10:00 EST (+2.63 pp intraday alpha vs. SPY) without triggering any post-catalyst over-extension gate finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗.

Compared with the next best viable finalists under the decider's synchronized forecast model:

  • vs. Procter & Gamble (PG, Rank #2): JNJ delivers higher base expected net return (+1.1609% vs. +0.8810%), higher uncertainty-adjusted excess return (-1.6391% vs. -1.8190%), higher Expected R (+0.4230 vs. +0.2827), and higher stressed SPY excess (+0.3103% vs. +0.1652%). PG's November 19 Investor Day left FY27 guidance unchanged rttnewsP&G Plans To Cut Up To 30% Jobs By 2030In its Investor Day on Thursday, the firm also maintained fiscal 2027 forecast for net sales growth of 2 to 4 percent and organic sales growth of 1 to 3 percent ...Visit original website ↗ and adding PG would severely overcrowd the portfolio's existing 25.36% Consumer Defensive weight (COST, TGT, WMT).
  • vs. Casey's General Stores (CASY, Rank #3): CASY offers cleaner Consumer Cyclical portfolio fit (8.29% weight) and virtually tied base expected return (+1.1444%), but relies on a November 17 Stifel Buy initiation ($800 PT marketbeatStifel Nicolaus Begins Coverage on Casey's General ...Stifel Nicolaus initiated coverage of Casey's General Stores with a “buy” rating and an $800 price target, implying 13.36% upside from the prior close. Analyst ...Visit original website ↗) rather than an issuer release, faces a declining $745.643 200-day moving average directly beneath its $760.52 1.8× profit barrier, carries Stifel-flagged Q1 fuel-margin peak risk barronsHow to Invest Around Consumer Resilience: Video... Casey's General Stores after a post-earnings drop. Teresa Rivas explained that prolonged high fuel prices limit fuel margin arbitrage and reduce store ...Visit original website ↗, and turns negative in stressed SPY excess (-0.1869% vs. JNJ +0.3103%).
  • vs. Lowe's (LOW, Rank #4), Erie Indemnity (ERIE, Rank #5), and Rollins (ROL, Rank #6): LOW carries wider 3.15 pp uncertainty and negative stressed excess (-0.5399%) due to a one-time $0.34 tariff refund embedded in Q3 EPS and a 10 bps FY26 margin trim; ERIE lacks a fresh catalyst and suffers thin intraday liquidity ($56.2M ADV); ROL carries the widest uncertainty deduction (3.80 pp) among the top six finalists with no fresh November 18–20 catalyst and a 3.52× ATR14 distance to its 1.8× profit barrier.

Business And Market Context

Johnson & Johnson operates across two global healthcare segments—Innovative Medicine (oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular/metabolism) and MedTech (surgery, orthopedics, cardiovascular, and vision, including robotic surgical platforms such as OTTAVA) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. With a $652.6B market capitalization, 2.01% dividend yield, and 0.20 beta finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗, JNJ functions as a core institutional defensive anchor during equity drawdowns.

The broad market backdrop on November 20 is a bifurcated risk-off tape rather than a confirmed broad-market crash: SPY ($707.190 at 11:10:00 EST) is down -1.21% intraday below its 200-day moving average ($730.199) as AI and semiconductor leaders unwind, while defensive healthcare and staples attract relative inflows finance.yahoYahoo Finance: State Street SPDR S&P 500 ETF TrustYahoo Finance quote pageVisit original website ↗. Macro event risk is concentrated inside the shortened Thanksgiving week:

In this macro-heavy, 4-session week, JNJ's 0.20 beta and confirmed $1.34 ex-dividend cash cushion provide superior relative insulation compared with higher-beta cyclical or technology alternatives. Portfolio-wise, JNJ adds to an existing 16.63% Healthcare allocation (ALGN, REGN), which is elevated but materially less crowded than Consumer Defensive (25.36%).

Factor Stack

Factor Sourced Observations Decider Assessment / Estimates
Catalyst / News Edge Four Nov 17–20 milestones (TREMFYA Phase 4 prnewswireJohnson & Johnson data in psoriatic arthritis (PsA) shows ...NEW BRUNSWICK, N.J., Nov. 20, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA ( ...Visit original website ↗, CAPLYTA sNDA jnjJohnson & Johnson Seeks U.S. FDA Approval for ...Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication. · Two positive Phase 3 studies showed CAPLYTA ...Visit original website ↗, OTTAVA first install quantisnowJohnson & Johnson Announces First Commercial ...Nov 16, 2026, Johnson & Johnson to acquire Ollin ... JNJ dividend history Dividends Johnson & Johnson has declared, with ex-dates and payment dates.Visit original website ↗, RYBREVANT FASPRO approval patientworthyFDA Approves RYBREVANT FASPRO for Some Adults ...As shared in a recent press statement by Johnson & Johnson, the U.S. Food and Drug Administration (FDA) has granted accelerated approval to RYBREVANT FASPRO ...Visit original website ↗), Nov 16 $5.5B talc framework ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗, and $1.34 Nov 24 ex-dividend investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗. Strong defensive/pipeline sentiment support; zero immediate 7-day EPS step-change.
Growth & Profitability Mega-cap scale ($652.6B market cap) with diversified Innovative Medicine and MedTech cash flows; 2.01% dividend yield finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. No solvency or liquidity concerns; $2.07B 20D average daily dollar volume supports tight execution (0.12% estimated friction).
Valuation Trailing P/E 41.13×, Forward P/E 23.34×, PEG 3.07, P/B 8.00× at $271.075 (11:21:00 EST) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. Not a deep-value discount; valuation is supported by defensive quality and pipeline durability rather than multiple expansion.
Momentum / Relative Strength 20D return +1.26% vs. SPY -5.80% (+7.06 pp alpha) and XLV -1.02% (+2.28 pp alpha) through Nov 19; above SMA50 ($267.330) and SMA200 ($250.664), slightly below SMA20 ($274.676) and session VWAP ($271.638 at 11:20 EST) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. Constructive pullback-and-rebound structure; over-extension gate not triggered.
Sentiment / Social Confirmation Constructive X.com commentary highlighting OTTAVA commercial installation xtenet researchJNJ Johnson & Johnson Announces First Commercial Installation of the OTTAVA™ Robotic Surgical System at Memorial Hermann Health System.Visit original website ↗, CAPLYTA sNDA xTENET RESEARCH on XJNJ - Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication.Visit original website ↗, Blackstone $750M collaboration xBlackstoneWe're pleased to expand our relationship with Johnson & Johnson through a $750 million agreement for Blackstone Life Sciences to support the Phase 3 ...Visit original website ↗, and 64-year Dividend Aristocrat safe-haven status xJohnson & Johnson $JNJ is up 49% over the past year and ...Johnson & Johnson $JNJ is up 49% over the past year and just closed at a new all-time high. That is not a tech stock. It is a 64-year Dividend Aristocrat, ...Visit original website ↗. Low short float (0.79%, 2.2 days to cover) finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗. Supportive institutional/retail defensive narrative; tempered by Nov 19 FDA Inlexzo marketing rebuke fiercepharmaJ&J draws FDA rebuke over Inlexzo bladder-sparing ...The FDA slammed J&J over misleading claims about its bladder cancer drug Inlexzo, accusing the company of basing statements on uninterpretable data.Visit original website ↗.
EPS Revisions / Estimates No fresh 7-day consensus EPS revision triggered by Nov 17–20 clinical/MedTech releases; Enterprise Business Review scheduled outside horizon on Dec 8, 2026 jnjJohnson & Johnson Enterprise Business ReviewRegister for Johnson & Johnson's Enterprise Business Review. Tuesday, December 8, 2026. Register and join. Innovating in Health&Care. inside-the-development-of ...Visit original website ↗. Unavailable near-term estimate revisions are explicitly acknowledged; thesis relies on defensive flow, dividend capture, and mean reversion.

Investment Thesis

The core investment thesis for buying JNJ now is an asymmetric, low-beta defensive total-return setup over the shortened November 20–27 week, driven by (1) institutional rotation into Healthcare during a bifurcated tech/AI drawdown, (2) four fresh November 17–20 clinical and MedTech execution milestones reinforcing pipeline sentiment, and (3) a confirmed $1.34/share (+0.495%) Q4 ex-dividend on Tuesday, November 24 investor.jnjJohnson & Johnson Announces Quarterly Dividend for Fourth ...Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026 ... The ex-dividend date is November 24, 2026. About Johnson & Johnson.Visit original website ↗ that anchors the highest-probability time-exit branch.

Decider Scenario & Benchmark Comparison (Uncalibrated Analyst Estimates, Referenced to $270.935 at 11:10:00 EST):

  • Actual Profit Barrier vs. T1 Reference: The decider's 7-day T1 reference target_price is $282.50 (+4.27%, November 16 close). Under the execution policy, the actual full-position profit exit is at 1.8× T1's percentage return, placing the profit barrier at $291.75 (+7.6836%, 2.97× ATR14, just above the $290.25 52-week high finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗). first_resistance_price at $275.05 (+1.52%, SMA20/VWAP20 confluence) is tracked separately as a path diagnostic. Because JNJ's 0.20 beta makes a +7.68% 4-session sprint low-probability, the decider assigns only 13.0% probability to the 1.8× profit barrier.
  • Time-Exit Branch (65.0% probability, +1.65% conditional return): The primary return engine is a controlled rebound above $275.05 SMA20/VWAP20 into the November 27 10:20:01 EST horizon, modeled at $274.06 ex-dividend price plus the confirmed $1.34 dividend ($275.40 total value, +1.65%). The dividend is credited once in this guaranteed post-ex-date branch and conservatively omitted from early stop or profit exits.
  • Stop-Exit Branch (22.0% probability, -3.59% conditional return): Authored structural stop at $263.50 (-2.74%, 1.06× ATR14, below the November 19 low of $264.68 and SMA50 of $267.33 finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), with conditional stop_exit_price modeled at $261.20 (-3.5931%) to account for confirmation delay and macro gap risk.
  • Net Expected Return & Stress Resilience: After 0.12% estimated friction, the decider's base expected net return is +1.1609% (+0.4609% excess vs. the decider's +0.70% 7-day SPY base estimate; Expected R +0.4230). Deducting the reconciled 2.10 pp edge_uncertainty_pct (which covers the 2.0306 pp stress minimum) yields -0.9391% conservative absolute return and -1.6391% uncertainty-adjusted excess return—still #1 among all 10 reviewed finalists. In a coherent adverse-market stress (SPY -1.18%), JNJ's stressed return (-0.8697%) still outperforms SPY by +0.3103%.

Risks And Thesis Breakers

  • Ex-Dividend Stop Proximity: Tuesday, November 24's mechanical -$1.34 ex-dividend price adjustment narrows the buffer to the $263.50 authored stop from $7.435 (1.06× ATR14) to $6.095 (0.87× ATR14). A weak tape on Monday/Tuesday could push JNJ into the stop confirmation zone even without fundamental deterioration.
  • Litigation & Regulatory Headline Overhang: Although Monday November 16's $5.5B talc settlement framework was constructive ddnews.gov.iJ&J reaches sweeping talc deal that could end decade ...Johnson & Johnson said on Monday it would pay an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its baby powder and other talc ...Visit original website ↗, a Louisiana appellate court upheld a multimillion-dollar mesothelioma talc verdict on November 17 businesswireLouisiana Appeals Court Upholds Millions in Damages ...Johnson & Johnson, in which a jury found that talc in its baby powder caused a New Orlean's woman's mesothelioma and death.Visit original website ↗, and on November 19 the FDA issued a marketing rebuke over promotional claims for bladder cancer drug Inlexzo fiercepharmaJ&J draws FDA rebuke over Inlexzo bladder-sparing ...The FDA slammed J&J over misleading claims about its bladder cancer drug Inlexzo, accusing the company of basing statements on uninterpretable data.Visit original website ↗ (accompanied by a routine investor-alert press release morningstarINVESTOR ALERT: Pomerantz Law Firm Investigates ...The investigation concerns whether J&J and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. to ...Visit original website ↗). Fresh adverse court rulings or expanded FDA enforcement would break the defensive-leadership thesis.
  • Macro Event & Gap Risk: The Wednesday, November 25 8:30 AM EST data cluster (Q3 GDP, October PCE/Core PCE, Durable Goods, Jobless Claims) bea.govRelease Schedule | U.S. Bureau of Economic Analysis (BEA)Release Schedule Upcoming Releases Full Schedule 2025 Schedule 2027 Schedule N ews Release D ata Release VVisit original website ↗census.govsourceVisit original website ↗oui.doleta.gOffice of Unemployment InsurancePrior versions of the News Release are available through the application tool below. Publication Schedule: The UI Weekly Claims News Release is published each ...Visit original website ↗ could trigger a broad-market gap below $263.50 or a sharp yield spike that pressures dividend equities.
  • Low-Beta Upside Cap & Intraday VWAP Slip: With 0.20 beta finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗ and current trading ($271.075 at 11:21:00 EST) slightly below session VWAP ($271.638 finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗), failure to reclaim $275.05 SMA20/VWAP20 would cap gains and leave the position vulnerable to drift.
  • Model & Calibration Limitations: All scenario probabilities, conditional returns, and benchmark forecasts are uncalibrated analyst estimates rather than empirically fitted frequencies. JNJ's uncertainty-adjusted excess return (-1.6391%) is negative, reflecting elevated Thanksgiving-week macro dispersion.
  • Binary-Event & Solvency Status: Zero pending company-specific binary events (earnings, FDA PDUFA, or court rulings) are scheduled inside November 20–27 (Enterprise Business Review is confirmed for December 8, 2026 jnjJohnson & Johnson Enterprise Business ReviewRegister for Johnson & Johnson's Enterprise Business Review. Tuesday, December 8, 2026. Register and join. Innovating in Health&Care. inside-the-development-of ...Visit original website ↗), and no liquidity or solvency risks are present.
  • Explicit Thesis Breakers: A sustained breakdown below the November 19 low ($264.68) and SMA50 ($267.33) that triggers the $263.50 stop confirmation, or a material new adverse talc/FDA regulatory development, invalidates the trade.

Investment Recommendation

Buy JNJ (Johnson & Johnson) now for a 1-slot position over the 7-calendar-day horizon (2026-11-20 10:20:01 EST to 2026-11-27 10:20:01 EST), with Medium confidence (descriptive only).

Execution & Stop-Loss Plan (authored_stop_ma60_confirm90_spot_mom15_hard15_confirm10_tp1p8_v2):

  • Reference Entry & Fresh Quote: Authored research entry $270.935 (2026-11-20 11:10:00 EST); latest publication check $271.075 (2026-11-20 11:21:00 EST, +0.05% drift, support unbroken finance.yahooYahoo Finance: Johnson & JohnsonYahoo Finance quote pageVisit original website ↗).
  • Authored Stop-Loss ($263.50, -2.74%): Placed below the November 19 low ($264.68) and SMA50 ($267.33). Under the execution policy, a soft stop exit requires the trailing 60-minute average price to remain at or below $263.50 for 90 consecutive minutes, with spot still at or below $263.50 and a nonpositive 15-minute price change (missing momentum evidence defers the soft exit; recovery checks preserve the confirmation timer until the 60-minute average recovers).
  • Hard-Loss Backstop & Slippage: A 15% hard-loss condition requires 10 minutes of confirmation. Neither the authored stop nor the hard-loss level guarantees an exact fill across overnight gaps or delayed confirmation; the decider models a conditional stop_exit_price of $261.20 (-3.59%) before execution friction, with 0.10% adverse slippage (0.12% total estimated friction).
  • Profit Target & Time Exit: Path diagnostic first_resistance_price is $275.05 (SMA20/VWAP20); strategy-horizon T1 reference target_price is $282.50 (+4.27%); the actual full-position profit barrier is $291.75 (1.8× T1's percentage return, +7.68%). Any early profit or stop exit leaves proceeds in cash through 2026-11-27 10:20:01 EST; otherwise, the position exits at the scheduled horizon on November 27 after capturing the November 24 $1.34 ex-dividend.

Financial Snapshot

As of Nov 20, 2026 Morning

Pr. $271.11
Market Cap 652.65B
P/E Ratio 41.14
52W High $290.25
52W Low $199.91
Volume 2.5M
Sector Healthcare
Dividend Yield 2.01%
Beta 0.20

References

Disclaimer: This is not financial advice. All investments carry risk. Please do your own research and consult with a financial advisor before making investment decisions.